Document is current
Any future updates will be listed below
-
Authors
Roy, Chad J. https://orcid.org/0000-0002-1710-6974
Ehrbar, Dylan https://orcid.org/0000-0001-7872-3338
Van Slyke, Greta
Doering, Jennifer
Didier, Peter J.
Doyle-Meyers, Lara
Donini, Oreola
Vitetta, Ellen S.
Mantis, Nicholas J. https://orcid.org/0000-0002-5083-8640
-
Funding
Funding for this research was provided by:
Division of Intramural Research, National Institute of Allergy and Infectious Diseases (AI125190)
U.S. Department of Health & Human Services | NIH | Office of Extramural Research, National Institutes of Health (OD011104)
U.S. Department of Health & Human Services | NIH | National Institute of Allergy and Infectious Diseases (HHSN272201400039C)
- License Information
-
More Information
Article History
Received: 18 April 2022
Accepted: 24 November 2022
First Online: 16 December 2022
Competing interests
: The authors declare no competing interests, except for OD, who is an employee of Soligenix, Inc., which holds the license for RiVax<sup>®</sup>.
